Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hyoscyamine SCHEMBL41316 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL41317 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL17775090 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL2728129 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL14946873 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL8854381 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL7941966 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL25020 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Atropine SCHEMBL2812 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| Hyoscyamine SCHEMBL4957671 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 930 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118453493-A | D2O-stabilized pharmaceutical formulations | 西德奈克西斯公司 | 2024-08-09 | — | — | CN | claimed |
| CN-113968853-B | Hapten and artificial antigen of atropine alkaloid, and preparation method and application thereof | 中国农业大学 | 2022-09-16 | — | — | CN | claimed |
| CN-113968853-A | Hapten and artificial antigen of atropine alkaloid, and preparation method and application thereof | 中国农业大学 | 2022-01-25 | — | — | CN | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| WO-2018189484-A1 | MATRIX FOR SPECIFIC DETECTION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | Université d'Angers (FR) | 2018-10-18 | — | — | WO | claimed |
| US-9155731-B1 | Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations | TRUIST BANK, AS ADMINISTRATIVE AGENT | 2015-10-13 | — | — | US | claimed |
| EP-2734514-B1 | USE OF A THIOPHENE COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | UNIV ANGERS (FR) | 2015-07-08 | — | — | EP | claimed |
| US-8946258-B1 | Methods of non-gastrointestinal endoscopic procedures using L-hyoscyamine oral formulations | TRUIST BANK, AS ADMINISTRATIVE AGENT | 2015-02-03 | — | — | US | claimed |
| US-20140319331-A1 | NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2014-10-30 | — | — | US | claimed |
| EP-2734514-A1 | NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | Centre National de la Recherche Scientifique (CNRS) (FR) | 2014-05-28 | — | — | EP | claimed |
| CN-101203250-A | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS INC (CA) | 2008-06-18 | — | — | CN | claimed |
| EP-1868664-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Interface Biologics Inc. (CA) | 2007-12-26 | — | — | EP | claimed |
| EP-1844158-A2 | BIOMARKER FOR INFLAMMATORY BOWEL DISEASE | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070037891-A1 | Methods and compositions for the delivery of biologically active agents | INTERFACE BIOLOGICS (CA) | 2007-02-15 | — | — | US | claimed |
| WO-2007004067-A2 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | INTERFACE BIOLOGICS INC. (CA) | 2007-01-11 | — | — | WO | claimed |
| WO-2006063133-A2 | BIOMARKER FOR INFLAMMATORY BOWEL DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-06-15 | — | — | WO | claimed |
| CN-1492761-A | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction | 美国医疗产品公司 | 2004-04-28 | — | — | CN | claimed |
| WO-2002069966-A1 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND REVERSAL OF ERECTILE DYSFUNCTION | USA DOCTORS PRODUCTS, INC. (US) | 2002-09-12 | — | — | WO | claimed |
| US-6197801-B1 | MIXTURE OF PROSTAGLANDIN E-1, LEVSIN, 6,7-DIMETHOXY-1-VERATYLISOQUINOLOINE HYDROCHLORIDE, DILTIAZEM HCL AND CHLORPROMAZINE | USA DOCTORS PRODUCTS, INC. | 2001-03-06 | — | — | US | claimed |
| US-4591573-A | REACTING L-HYOSCYAMINE WITH DIAZOTIZED P-AMINOBENZOIC ACID TO PRODUCE HAPTEN | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1986-05-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140319331-A1 | NEW USE FOR A COMPOUND AS A MATRIX IN THE SPECIFIC DETECTION, IDENTIFICATION AND/OR QUANTIFICATION OF ALKALOIDS BY MALDI-TOF MASS SPECTROMETRY | CIAPIN1, SRMS, MMP7 | CHRM1 1582/4885CHRM2 1237/4885CHRM3 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.